Cancer Genetics Inc (CGIX) 1.96 $CGIX
Cancer Genetics, Inc. and Sayre Therapeutics Announce Distribution Agreement to Commercialize CGI's Proprietary FDA-cleared Tissue of Origin (TOO(R)) Test Throughout India and South Asia
GlobeNewswire - Thu Jun 23, 7:25AM CDT
-- TOO(R) is the ONLY FDA-cleared test of its type, used to aid in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. to Present at the 2016 LD Micro Invitational Investor Conference
GlobeNewswire - Tue Jun 07, 6:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at LD Micro's Sixth Invitational Conference on Wednesday, June 8, 2016 at 11:00 AM Pacific Time, at the Luxe Sunset Bel Air in Los Angeles, CA.
CGIX: 1.96 (-0.08)
HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
GlobeNewswire - Mon Jun 06, 7:00AM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) ("HTG" , a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3-7, 2016 in Chicago, IL.
HTGM: 2.43 (+0.01), CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Partners with ArcherDX to Offer Archer(R) NGS Assays as a Sequencing Service for Biotech and Pharma
BusinessWire - Thu Jun 02, 7:51AM CDT
ArcherDX, Inc., a leader in NGS-based gene fusion detection, has announced that Cancer Genetics, Inc., (CGI) has become a Certified Service Provider of Archer(R) FusionPlex(R) NGS assays. Additionally, CGI plans to use Archer VariantPlex(TM) assays to identify copy number variants (CNVs) and point mutations in tumor samples and will be testing these assays in cell-free variant detection.
CGIX: 1.96 (-0.08)
Cancer Genetics Announces $5 Million Registered Direct Offering
GlobeNewswire - Fri May 20, 8:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("Cancer Genetics" or the "Company" , an emerging leader in DNA-based cancer diagnostics, today announced that it has entered into definitive agreements with healthcare focused institutional investors for an offering of 2.5 million shares of common stock with gross proceeds of approximately $5 million in a registered direct offering.
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel in Precision Medicine, FOCUS::Lymphoma (TM)
GlobeNewswire - Tue May 17, 6:30AM CDT
-- FOCUS::Lymphoma(TM) panel is being used to power several clinical trials with biotech and pharmaceutical companies, and is now available for use in a clinical setting
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Announces 39% Revenue Increase and Provides Recent Company Highlights
GlobeNewswire - Tue May 10, 4:06PM CDT
-- Company reports record quarterly revenues of $6.1 million, an increase of 39% over Q1 2015 and 11% over Q4 2015
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. to Present at Pioneers 2016 Conference Presented by Joseph Gunnar & Co., LLC
GlobeNewswire - Thu May 05, 6:14AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at the Pioneers 2016 Conference presented by Joseph Gunnar & Co., LLC on Thursday, May 5, 2016 at 8:30 AM Eastern Time, at the New York Palace Hotel in New York City.
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies
GlobeNewswire - Wed May 04, 7:34AM CDT
-- CGI is uniquely positioned to deliver comprehensive immune marker and genomic data in oncology for biopharma partners and clinical centers for both solid and blood cancers
CGIX: 1.96 (-0.08)
Cancer Genetics to Report First Quarter 2016 Financial Results on Tuesday, May 10th
GlobeNewswire - Tue May 03, 6:36PM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 after the market close on Tuesday, May 10, 2016. The company will also hold a live investor conference call and webcast at 5:00 pm Eastern.
CGIX: 1.96 (-0.08)
4 Hot Stocks to Keep an Eye Out For in Medical Services
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 8:15AM CDT
A gradual transformation from providing volume to value-based-care model is underway, which is expected to bring in a revolutionary change in the healthcare service system.
PRXL: 66.85 (+0.02), PRAH: 46.38 (+2.50), ICLR: 77.67 (-1.02), CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. to Present at 28th Annual ROTH Conference on March 16, 2016
GlobeNewswire - Mon Mar 14, 6:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in enabling precision medicine for oncology diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at the 28 Annual ROTH Conference on Wednesday, March 16, 2016, at 9:30 AM Pacific Time/12:30 PM Eastern Time, at the Ritz Carlton in Dana Point, CA.
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update
GlobeNewswire - Thu Mar 10, 2:53PM CST
-- Full-Year 2015 revenues up 77% year-over-year to $18 Million
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Launches Next Generation Sequencing Panel for Diagnosis & Treatment Selection in Solid Tumors, CGI FOCUS::Oncomine(TM)
GlobeNewswire - Mon Mar 07, 8:37AM CST
-- CGI has launched the next-generation sequencing (NGS) panel with CLIA validation and will perform the test for both clinical care and for trials being performed by biotech and pharmaceutical companies
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota
GlobeNewswire - Fri Feb 05, 7:00AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Minnesota ("BCBS of Minnesota" . As part of the agreement, the over 2.6 million members of the Blue Cross Blue Shield plan will have access to CGI's cancer diagnostics and genomic testing services.
CGIX: 1.96 (-0.08)
Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use In Clinical Trials, Translational Research, and Therapy Selection For Patients
M2 - Fri Jan 22, 4:20AM CST
* Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially impact up to 60% of all cancer patients
CGIX: 1.96 (-0.08)
Molecular Diagnostics in Cancer Testing 2016 - New Technologies and Applications Being Continually Added
M2 - Wed Jan 13, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/2m62l5/molecular) has announced the addition of the "Molecular Diagnostics in Cancer Testing" report to their offering. Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 6. Reimbursement and Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development 9. Company Profiles Companies Mentioned - Abbott Molecular Diagnostics - Accugenomics, Inc. - Agendia - Ambry Genetics - Biodesix - bioM?rieux - bioTheranostics (AviaraDx) - Cancer Genetics, Inc. - Clarient, Inc. (GE Healthcare) - Counsyl - Flatiron Health - Epigenomics - Exact Sciences Corporation - Exiqon - Genomic Health, Inc. - Genoptix, Inc. (Novartis) - Genmark Diagnostics - Genomictree - HTG Molecular Diagnostics - Invitae - LabCorp - Myriad Genetics, Inc. - Nanostring - Neogenomics - NSTG - Nuvera Biosciences - Orion Genomics - Pathway Genomics - Personal Genome Diagnostics - Quest Diagnostics - Rosetta Genomics Ltd. - Signal Genetics - Source MDx - Wilex, Inc. For more information visit http://www.researchandmarkets.com/research/2m62l5/molecular
SGNL: 0.49 (-0.03), MYGN: 30.98 (-1.09), DGX: 86.36 (+1.05), HTGM: 2.43 (+0.01), EXAS: 17.38 (+0.06), GHDX: 29.03 (+0.30), CGIX: 1.96 (-0.08), NVS: 83.26 (+1.18)
Cancer Genetics, Inc. (CGI) to Present Results of Collaborative Renal Biopsy and Clear Cell Renal Cell Carcinoma (ccRCC) Studies at the 2016 Genitourinary Cancer Symposium
GlobeNewswire - Wed Jan 06, 5:22PM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , an emerging leader in DNA-based cancer diagnostics announced the presentation of results from collaborative studies with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. The first study focuses on actionable diagnostic and prognostic information provided by CGI's proprietary next-generation sequencing panel using renal cancer biopsies. The second study focuses on identification of somatic variants in metastatic clear cell renal cell carcinoma patients. Posters with results of both studies will be presented during the 2016 Genitourinary Cancers Symposium, on January 7-9, 2016 in San Francisco, CA.
CGIX: 1.96 (-0.08)
New Strong Sell Stocks for January 6th
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BCC: 27.17 (+0.20), CARO: 19.13 (-0.93), ACBI: 14.83 (-0.09), CGIX: 1.96 (-0.08), HRB: 23.79 (-0.26)
Cancer Genetics, Inc. and Sayre Therapeutics Announce Distribution Agreement to Commercialize CGI's Proprietary FDA-cleared Tissue of Origin (TOO(R)) Test Throughout India and South Asia
GlobeNewswire - Thu Jun 23, 7:25AM CDT
-- TOO(R) is the ONLY FDA-cleared test of its type, used to aid in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. to Present at the 2016 LD Micro Invitational Investor Conference
GlobeNewswire - Tue Jun 07, 6:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at LD Micro's Sixth Invitational Conference on Wednesday, June 8, 2016 at 11:00 AM Pacific Time, at the Luxe Sunset Bel Air in Los Angeles, CA. CGIX: 1.96 (-0.08)
HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
GlobeNewswire - Mon Jun 06, 7:00AM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) ("HTG"
, a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3-7, 2016 in Chicago, IL. HTGM: 2.43 (+0.01), CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Partners with ArcherDX to Offer Archer(R) NGS Assays as a Sequencing Service for Biotech and Pharma
BusinessWire - Thu Jun 02, 7:51AM CDT
ArcherDX, Inc., a leader in NGS-based gene fusion detection, has announced that Cancer Genetics, Inc., (CGI) has become a Certified Service Provider of Archer(R) FusionPlex(R) NGS assays. Additionally, CGI plans to use Archer VariantPlex(TM) assays to identify copy number variants (CNVs) and point mutations in tumor samples and will be testing these assays in cell-free variant detection.
CGIX: 1.96 (-0.08)
Cancer Genetics Announces $5 Million Registered Direct Offering
GlobeNewswire - Fri May 20, 8:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("Cancer Genetics" or the "Company"
, an emerging leader in DNA-based cancer diagnostics, today announced that it has entered into definitive agreements with healthcare focused institutional investors for an offering of 2.5 million shares of common stock with gross proceeds of approximately $5 million in a registered direct offering. CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel in Precision Medicine, FOCUS::Lymphoma (TM)
GlobeNewswire - Tue May 17, 6:30AM CDT
-- FOCUS::Lymphoma(TM) panel is being used to power several clinical trials with biotech and pharmaceutical companies, and is now available for use in a clinical setting
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Announces 39% Revenue Increase and Provides Recent Company Highlights
GlobeNewswire - Tue May 10, 4:06PM CDT
-- Company reports record quarterly revenues of $6.1 million, an increase of 39% over Q1 2015 and 11% over Q4 2015
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. to Present at Pioneers 2016 Conference Presented by Joseph Gunnar & Co., LLC
GlobeNewswire - Thu May 05, 6:14AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at the Pioneers 2016 Conference presented by Joseph Gunnar & Co., LLC on Thursday, May 5, 2016 at 8:30 AM Eastern Time, at the New York Palace Hotel in New York City. CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies
GlobeNewswire - Wed May 04, 7:34AM CDT
-- CGI is uniquely positioned to deliver comprehensive immune marker and genomic data in oncology for biopharma partners and clinical centers for both solid and blood cancers
CGIX: 1.96 (-0.08)
Cancer Genetics to Report First Quarter 2016 Financial Results on Tuesday, May 10th
GlobeNewswire - Tue May 03, 6:36PM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 after the market close on Tuesday, May 10, 2016. The company will also hold a live investor conference call and webcast at 5:00 pm Eastern.
CGIX: 1.96 (-0.08)
4 Hot Stocks to Keep an Eye Out For in Medical Services
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 8:15AM CDT
A gradual transformation from providing volume to value-based-care model is underway, which is expected to bring in a revolutionary change in the healthcare service system.
PRXL: 66.85 (+0.02), PRAH: 46.38 (+2.50), ICLR: 77.67 (-1.02), CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. to Present at 28th Annual ROTH Conference on March 16, 2016
GlobeNewswire - Mon Mar 14, 6:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in enabling precision medicine for oncology diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at the 28 Annual ROTH Conference on Wednesday, March 16, 2016, at 9:30 AM Pacific Time/12:30 PM Eastern Time, at the Ritz Carlton in Dana Point, CA.
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update
GlobeNewswire - Thu Mar 10, 2:53PM CST
-- Full-Year 2015 revenues up 77% year-over-year to $18 Million
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Launches Next Generation Sequencing Panel for Diagnosis & Treatment Selection in Solid Tumors, CGI FOCUS::Oncomine(TM)
GlobeNewswire - Mon Mar 07, 8:37AM CST
-- CGI has launched the next-generation sequencing (NGS) panel with CLIA validation and will perform the test for both clinical care and for trials being performed by biotech and pharmaceutical companies
CGIX: 1.96 (-0.08)
Cancer Genetics, Inc. Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota
GlobeNewswire - Fri Feb 05, 7:00AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Minnesota ("BCBS of Minnesota" . As part of the agreement, the over 2.6 million members of the Blue Cross Blue Shield plan will have access to CGI's cancer diagnostics and genomic testing services. CGIX: 1.96 (-0.08)
Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use In Clinical Trials, Translational Research, and Therapy Selection For Patients
M2 - Fri Jan 22, 4:20AM CST
* Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially impact up to 60% of all cancer patients
CGIX: 1.96 (-0.08)
Molecular Diagnostics in Cancer Testing 2016 - New Technologies and Applications Being Continually Added
M2 - Wed Jan 13, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/2m62l5/molecular) has announced the addition of the "Molecular Diagnostics in Cancer Testing" report to their offering. Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 6. Reimbursement and Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development 9. Company Profiles Companies Mentioned - Abbott Molecular Diagnostics - Accugenomics, Inc. - Agendia - Ambry Genetics - Biodesix - bioM?rieux - bioTheranostics (AviaraDx) - Cancer Genetics, Inc. - Clarient, Inc. (GE Healthcare) - Counsyl - Flatiron Health - Epigenomics - Exact Sciences Corporation - Exiqon - Genomic Health, Inc. - Genoptix, Inc. (Novartis) - Genmark Diagnostics - Genomictree - HTG Molecular Diagnostics - Invitae - LabCorp - Myriad Genetics, Inc. - Nanostring - Neogenomics - NSTG - Nuvera Biosciences - Orion Genomics - Pathway Genomics - Personal Genome Diagnostics - Quest Diagnostics - Rosetta Genomics Ltd. - Signal Genetics - Source MDx - Wilex, Inc. For more information visit http://www.researchandmarkets.com/research/2m62l5/molecular
SGNL: 0.49 (-0.03), MYGN: 30.98 (-1.09), DGX: 86.36 (+1.05), HTGM: 2.43 (+0.01), EXAS: 17.38 (+0.06), GHDX: 29.03 (+0.30), CGIX: 1.96 (-0.08), NVS: 83.26 (+1.18)
Cancer Genetics, Inc. (CGI) to Present Results of Collaborative Renal Biopsy and Clear Cell Renal Cell Carcinoma (ccRCC) Studies at the 2016 Genitourinary Cancer Symposium
GlobeNewswire - Wed Jan 06, 5:22PM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, an emerging leader in DNA-based cancer diagnostics announced the presentation of results from collaborative studies with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. The first study focuses on actionable diagnostic and prognostic information provided by CGI's proprietary next-generation sequencing panel using renal cancer biopsies. The second study focuses on identification of somatic variants in metastatic clear cell renal cell carcinoma patients. Posters with results of both studies will be presented during the 2016 Genitourinary Cancers Symposium, on January 7-9, 2016 in San Francisco, CA. CGIX: 1.96 (-0.08)
New Strong Sell Stocks for January 6th
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BCC: 27.17 (+0.20), CARO: 19.13 (-0.93), ACBI: 14.83 (-0.09), CGIX: 1.96 (-0.08), HRB: 23.79 (-0.26)
